Overt Hepatic Encephalopathy Market Research Report - Global Forecast till 2027

Overt Hepatic Encephalopathy Market Research Report: Information by Type (Covert and Overt), Disease Severity (Type A, Type B and Type C), Diagnosis (Blood Test, Liver Function Test, Detection of Serum Ammonia Levels, Encephalogram and others), Treatment (Lactulose, Antibiotics, Probiotics, Branched-Chain Amino Acids, Liver Transplantation and others), End User (Hospitals & Clinics, Research Institutes, Surgical Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/0280-HCR | February 2021 | Region: Global | 95 pages

Market Scenario


Overt Hepatic Encephalopathy Market is expected to register 11.2% CAGR during the forecast period of 2019 to 2025 and held a market value of USD 54.28 Million in 2018.


Hepatic encephalopathy is a neuropsychiatric complication that occurs in patients with end-stage liver disease. It develops in approximately 50% of patients who have cirrhosis. Factors responsible for development of over hepatic encephalopathy include gastrointestinal bleeding, metabolic disturbance, and liver infection. Around 30 million people in the US are diagnosed with some form of overt hepatic encephalopathy disease annually.


The global overt hepatic encephalopathy market is driven by factors such as the prevalence of cirrhosis, rising cases of road traffic accidents, and increasing healthcare expenditure. For instance, according to the World Health Organization (WHO) report 2018, about 30–45% patients suffer from overt hepatic encephalopathy in the US. On the other hand, the availability of traditional treatment methods is expected to hamper the growth of the global market during the assessment period.


Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to maintain their position in the market.


Segmentation


The Global Overt Hepatic Encephalopathy Market has been segmented based on type, disease security, diagnosis, treatment, end user, and region.


The global overt hepatic encephalopathy market, based on type, has been divided into covert and overt. The overt segment is expected to hold a major share in the market due to the rising prevalence of liver disease globally.


The global overt hepatic encephalopathy market, based on disease security, has been segmented into Type A, Type B, and Type C.


The global overt hepatic encephalopathy market, based on diagnosis, has been segmented into blood tests, liver function test, detection of serum ammonia levels, encephalogram, and others.


The global overt hepatic encephalopathy market, based on treatment, is divided into lactulose, antibiotics, probiotics, branched-chain amino acids, liver transplantation, and others.


Based on end user, the global overt hepatic encephalopathy market is segmented into hospitals & clinics, research institutes, surgical centers, and others.


The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The overt hepatic encephalopathy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European overt hepatic encephalopathy market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The overt hepatic encephalopathy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The overt hepatic encephalopathy market in the Middle East & Africa has been divided into the Middle East and Africa.


Key Players


The Key Players operating in the Global Overt Hepatic Encephalopathy Market are Alfa Wassermann S.P.A, Cosmo Pharmaceuticals S.P.A, Horizon Pharma Plc., KannaLife Sciences, Inc., Ocer Therapeutics, Rebiotix Inc., Spherium Biomed S.L, Umecrine Cognition AB, ASKA Pharmaceutical, Mallinckrodt, Valeant, and Norgine B.V.


Regional Market Summary


Global Overt Hepatic Encephalopathy Market Share, by Region, 2018 (%)  Overt Hepatic Encephalopathy Market


Source: World Health Organization (WHO)


The Americas are expected to dominate the market during the forecast period due to the growing number of geriatric individuals and the presence of major established players in the region. Moreover, the developed healthcare infrastructure in the US is expected to drive the growth of the market in the region.


The overt hepatic encephalopathy market in Europe showed a considerable amount of growth, which can be attributed to the presence of a well-established healthcare system, increasing diagnosis of liver diseases, and the presence of major companies in the region.


The overt hepatic encephalopathy market in Asia-Pacific is projected to register a steady growth rate during the forecast period owing to the growing hepatic encephalopathy patient pool and increasing government initiatives for healthcare reforms.


The overt hepatic encephalopathy market in the Middle East & Africa is projected to account for the least share of the market due to the low per capita disposable income in the region.


Global Overt Hepatic Encephalopathy Market, by Type



  • Covert

  • Overt


Global Overt Hepatic Encephalopathy Market, by Disease Severity



  • Type A 

  • Type B

  • Type C


Global Overt Hepatic Encephalopathy Market, by Diagnosis



  • Blood Tests

  • Liver Function Test

  • Detection of Serum Ammonia Levels

  • Encephalogram

  • Others


Global Overt Hepatic Encephalopathy Market, by Treatment



  • Lactulose

  • Antibiotics

  • Probiotics

  • Branched-Chain Amino Acids

  • Liver Transplantation

  • Others


Global Overt Hepatic Encephalopathy Market, by End User  



  • Hospitals & Clinics

  • Research Institutes

  • Surgical Centers

  • Others


Global Overt Hepatic Encephalopathy Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Research and development (R&D) companies

  • Government research institutes

  • Academic institutes and universities

  • Venture capitalists



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 54.28 Million
  • 2027: Significant Value
  •   CAGR   11.2% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Disease Severity, Diagnosis, Treatment and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Alfa Wassermann S.P.A, Cosmo Pharmaceuticals S.P.A, Horizon Pharma Plc., KannaLife Sciences, Inc., Ocer Therapeutics, Rebiotix Inc., Spherium Biomed S.L, Umecrine Cognition AB, ASKA Pharmaceutical, Mallinckrodt, Valeant, and Norgine B.V
      Key Market Opportunities   scope for companies to introduce better drugs which help to cure the disease
      Key Market Drivers

  • prevalence of cirrhosis
  • rising cases of road traffic accidents
  • increasing healthcare expenditure


  • Speak to Analyst Ask for Customization

    Table of Contents

    1. REPORT PROLOGUE

    2. MARKET INTRODUCTION

    2.1. Definition

    2.2. Scope of the Study

    2.2.1. Research Objective

    2.2.2. Assumptions

    2.2.3. Limitations

    3. RESEARCH METHODOLOGY

    3.1. Overview

    3.2. Primary Research

    3.3. Secondary Research

    3.4. Market Size Estimation

    4. MARKET DYNAMICS

    4.1. Overview

    4.2. Drivers

    4.3. Restraints

    4.4. Opportunities

    5. MARKET FACTOR ANALYSIS

    5.1. Porter’s Five Forces Analysis

    5.1.1. Bargaining Power of Suppliers

    5.1.2. Bargaining Power of Buyers

    5.1.3. Threat of New Entrants

    5.1.4. Threat of Substitutes

    5.1.5. Intensity of Rivalry

    5.2. Value Chain Analysis

    6. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE

    6.1. Overview

    6.2. Covert

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3. Overt

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY

    7.1. Overview

    7.2. Type A

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3. Type B

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4. Type C

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS

    8.1. Overview

    8.2. Blood Tests

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3. Liver Function Test

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4. Detection of Serum Ammonia Levels

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.5. Encephalogram

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.6. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT

    9.1. Overview

    9.2. Lactulose

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.3. Antibiotics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.4. Probiotics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.5. Branched-Chain Amino Acids

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.6. Liver Transplantation

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.7. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER

    10.1. Overview

    10.2. Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10.3. Research Institutes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10.4. Surgical Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10.5. Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    11. GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY REGION

    11.1. Overview

    11.2. Americas

    11.2.1. North America

    11.2.1.1. US

    11.2.1.2. Canada

    11.2.2. Latin America

    11.3. Europe

    11.3.1. Western Europe

    11.3.1.1. Germany

    11.3.1.2. France

    11.3.1.3. Italy

    11.3.1.4. Spain

    11.3.1.5. UK

    11.3.1.6. Rest of Western Europe

    11.3.2. Eastern Europe

    11.4. Asia-Pacific

    11.4.1. Japan

    11.4.2. China

    11.4.3. India

    11.4.4. Australia

    11.4.5. South Korea

    11.4.6. Rest of Asia-Pacific

    11.5. Middle East & Africa

    11.5.1. Middle East

    11.5.2. Africa

    12. COMPANY LANDSCAPE

    12.1.1. Overview

    12.1.2. Competitive Analysis

    13. COMPANY PROFILE

    13.1. Alfa Wassermann S.P.A

    13.1.1. Overview

    13.1.2. Product Overview

    13.1.3. Financial Overview

    13.1.4. Key Developments

    13.1.5. SWOT Analysis

    13.1.6. Key Strategies

    13.2. Cosmo Pharmaceuticals S.P.A

    13.2.1. Overview

    13.2.2. Product Overview

    13.2.3. Financial Overview

    13.2.4. Key Developments

    13.2.5. SWOT Analysis

    13.2.6. Key Strategies

    13.3. Horizon Pharma Plc.

    13.3.1. Overview

    13.3.2. Product Overview

    13.3.3. Financial Overview

    13.3.4. Key Developments

    13.3.5. SWOT Analysis

    13.3.6. Key Strategies

    13.4. KannaLife Sciences, Inc.

    13.4.1. Overview

    13.4.2. Product Overview

    13.4.3. Financial Overview

    13.4.4. Key Developments

    13.4.5. SWOT Analysis

    13.4.6. Key Strategies

    13.5. Ocer Therapeutics

    13.5.1. Overview

    13.5.2. Product Overview

    13.5.3. Financial Overview

    13.5.4. Key Developments

    13.5.5. SWOT Analysis

    13.5.6. Key Strategies

    13.6. Rebiotix Inc.

    13.6.1. Overview

    13.6.2. Product Overview

    13.6.3. Financial Overview

    13.6.4. Key Developments

    13.6.5. SWOT Analysis

    13.6.6. Key Strategies

    13.7. Spherium Biomed S.L

    13.7.1. Overview

    13.7.2. Product Overview

    13.7.3. Financial Overview

    13.7.4. Key Developments

    13.7.5. SWOT Analysis

    13.7.6. Key Strategies

    13.8. Umecrine Cognition AB

    13.8.1. Overview

    13.8.2. Product Overview

    13.8.3. Financial Overview

    13.8.4. Key Developments

    13.8.5. SWOT Analysis

    13.8.6. Key Strategies

    13.9. ASKA Pharmaceutical

    13.9.1. Overview

    13.9.2. Product Overview

    13.9.3. Financial Overview

    13.9.4. Key Developments

    13.9.5. SWOT Analysis

    13.9.6. Key Strategies

    13.10. Mallinckrodt

    13.10.1. Overview

    13.10.2. Product Overview

    13.10.3. Financial Overview

    13.10.4. Key Developments

    13.10.5. SWOT Analysis

    13.10.6. Key Strategies

    13.11. Valeant

    13.11.1. Overview

    13.11.2. Product Overview

    13.11.3. Financial Overview

    13.11.4. Key Developments

    13.11.5. SWOT Analysis

    13.11.6. Key Strategies

    13.12. Norgine B.V.

    13.12.1. Overview

    13.12.2. Product Overview

    13.12.3. Financial Overview

    13.12.4. Key Developments

    13.12.5. SWOT Analysis

    13.12.6. Key Strategies

    14. APPENDIX

    14.1. References

    14.2. Related Reports


    LIST OF TABLES

    TABLE 1 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SYNOPSIS, 2020-2027

    TABLE 2 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 6 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 7 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 8 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 9 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 10 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 11 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 12 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 13 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 14 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

    TABLE 15 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 16 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 17 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 18 US: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 19 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 20 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 21 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 22 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 23 CANADA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 24 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

    TABLE 25 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 26 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 27 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 28 LATIN AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 29 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 30 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 31 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 32 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 33 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 34 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 35 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 36 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 37 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 38 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 39 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 40 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 41 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 42 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 43 EASTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 44 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 45 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 46 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 47 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 48 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)

    TABLE 49 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 50 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DISEASE SEVERITY, 2020-2027 (USD MILLION)

    TABLE 51 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

    TABLE 52 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 53 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET, BY END USER, 2020-2027 (USD MILLION)  

    LIST OF FIGURES

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET STRUCTURE OF THE GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET

    FIGURE 3 MARKET DYNAMICS OF THE GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET

    FIGURE 4 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY TYPE, 2020 (%)

    FIGURE 5 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY DISEASE SEVERITY, 2020 (%)

    FIGURE 6 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY DIAGNOSIS, 2020 (%)

    FIGURE 7 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY TREATMENT, 2020 (%)

    FIGURE 8 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY END USER, 2020 (%)

    FIGURE 9 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 10 NORTH AMERICA: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 11 EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 12 WESTERN EUROPE: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 13 ASIA-PACIFIC: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY COUNTRY, 2020 (%)

    FIGURE 14 MIDDLE EAST & AFRICA: OVERT HEPATIC ENCEPHALOPATHY MARKET SHARE, BY REGION, 2020 (%)

    FIGURE 15 GLOBAL OVERT HEPATIC ENCEPHALOPATHY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 16 ALFA WASSERMANN S.P.A: KEY FINANCIALS

    FIGURE 17 ALFA WASSERMANN S.P.A: SEGMENTAL REVENUE

    FIGURE 18 ALFA WASSERMANN S.P.A: REGIONAL REVENUE

    FIGURE 19 COSMO PHARMACEUTICALS S.P.A: KEY FINANCIALS

    FIGURE 20 COSMO PHARMACEUTICALS S.P.A: SEGMENTAL REVENUE

    FIGURE 21 COSMO PHARMACEUTICALS S.P.A: REGIONAL REVENUE

    FIGURE 22 HORIZON PHARMA PLC.: KEY FINANCIALS

    FIGURE 23 HORIZON PHARMA PLC.: SEGMENTAL REVENUE

    FIGURE 24 HORIZON PHARMA PLC.: REGIONAL REVENUE

    FIGURE 25 KANNALIFE SCIENCES, INC.: KEY FINANCIALS

    FIGURE 26 KANNALIFE SCIENCES, INC.: SEGMENTAL REVENUE

    FIGURE 27 KANNALIFE SCIENCES, INC.: REGIONAL REVENUE

    FIGURE 28 OCER THERAPEUTICS: KEY FINANCIALS

    FIGURE 29 OCER THERAPEUTICS: SEGMENTAL REVENUE

    FIGURE 30 OCER THERAPEUTICS: REGIONAL REVENUE

    FIGURE 31 REBIOTIX INC.: KEY FINANCIALS

    FIGURE 32 REBIOTIX INC.: SEGMENTAL REVENUE

    FIGURE 33 REBIOTIX INC.: REGIONAL REVENUE

    FIGURE 34 SPHERIUM BIOMED S.L: KEY FINANCIALS

    FIGURE 35 SPHERIUM BIOMED S.L: SEGMENTAL REVENUE

    FIGURE 36 SPHERIUM BIOMED S.L: REGIONAL REVENUE

    FIGURE 37 UMECRINE COGNITION AB: KEY FINANCIALS

    FIGURE 38 UMECRINE COGNITION AB: SEGMENTAL REVENUE

    FIGURE 39 UMECRINE COGNITION AB: REGIONAL REVENUE

    FIGURE 40 ASKA PHARMACEUTICAL: KEY FINANCIALS

    FIGURE 41 ASKA PHARMACEUTICAL: SEGMENTAL REVENUE

    FIGURE 42 ASKA PHARMACEUTICAL: REGIONAL REVENUE

    FIGURE 43 MALLINCKRODT: KEY FINANCIALS

    FIGURE 44 MALLINCKRODT: SEGMENTAL REVENUE

    FIGURE 45 MALLINCKRODT: REGIONAL REVENUE

    FIGURE 46 VALEANT: KEY FINANCIALS

    FIGURE 47 VALEANT: SEGMENTAL REVENUE

    FIGURE 48 VALEANT: REGIONAL REVENUE

    FIGURE 49 NORGINE B.V.: KEY FINANCIALS

    FIGURE 50 NORGINE B.V.: SEGMENTAL REVENUE

    FIGURE 51 NORGINE B.V.: REGIONAL REVENUE